Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Astria Therapeutics Inc.

    NASDAQ: ATXS · Real-Time Price · USD
    5.64
    -0.29 (-4.89%)
    At close: Jun 17, 2025, 1:17 PM

    Astria Therapeutics Statistics

    Share Statistics

    Astria Therapeutics has 56.43M shares outstanding. The number of shares has increased by 2.77% in one year.

    Shares Outstanding

    n/a
    		 56.43M

    Shares Change (YoY)

    n/a
    		 2.77%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 45.57M

    Failed to Deliver (FTD) Shares

    n/a
    		 16

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 3.02M, so 5.35% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 3.02M

    Short % of Shares Out

    n/a
    		 5.35%

    Short % of Float

    n/a
    		 6.73%

    Short Ratio (days to cover)

    n/a
    		 4.58

    Valuation Ratios

    The PE ratio is -5.33 and the forward PE ratio is -2.45. Astria Therapeutics's PEG ratio is 0.17.

    PE Ratio

    n/a
    		 -5.33

    Forward PE

    n/a
    		 -2.45

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 1.3

    PB Ratio

    n/a
    		 1.57

    P/FCF Ratio

    n/a
    		 -6.16

    PEG Ratio

    n/a
    		 0.17
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Astria Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 17.49, with a Debt / Equity ratio of 0.02.

    Current Ratio

    n/a
    		 17.49

    Quick Ratio

    n/a
    		 17.49

    Debt / Equity

    n/a
    		 0.02

    Debt / EBITDA

    n/a
    		 -0.06

    Debt / FCF

    n/a
    		 -0.07

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,208,461.54

    Employee Count

    n/a
    		 78

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -32.84% in the last 52 weeks. The beta is 0.38, so Astria Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.38

    52-Week Price Change

    n/a
    		 -32.84%

    50-Day Moving Average

    n/a
    		 4.67

    200-Day Moving Average

    n/a
    		 8.07

    Relative Strength Index (RSI)

    n/a
    		 65.4

    Average Volume (20 Days)

    n/a
    		 481,595

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -111.56M

    Net Income

    n/a
    		 -94.26M

    EBITDA

    n/a
    		 -94.26M

    EBIT

    n/a
    		 -94.26M

    Earnings Per Share (EPS)

    n/a
    		 -1.67
    Full Income Statement

    Balance Sheet

    The company has 59.82M in cash and 5.35M in debt, giving a net cash position of 54.47M.

    Cash & Cash Equivalents

    n/a
    		 59.82M

    Total Debt

    n/a
    		 5.35M

    Net Cash

    n/a
    		 54.47M

    Retained Earnings

    n/a
    		 -674.79M

    Total Assets

    n/a
    		 310.39M

    Working Capital

    n/a
    		 285.54M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -81.21M and capital expenditures -325K, giving a free cash flow of -81.54M.

    Operating Cash Flow

    n/a
    		 -81.21M

    Capital Expenditures

    n/a
    		 -325K

    Free Cash Flow

    n/a
    		 -81.54M

    FCF Per Share

    n/a
    		 -1.45
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    ATXS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ATXS is $28, which is 372.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $28

    Price Target Difference

    n/a
    		 372.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 7
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Aug 20, 2021. It was a backward split with a ratio of 1:6.

    Last Split Date

    n/a
    		 Aug 20, 2021

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:6

    Scores

    Altman Z-Score

    n/a
    		 3.6

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist